Charles Smith to Enzyme Inhibitors
This is a "connection" page, showing publications Charles Smith has written about Enzyme Inhibitors.
Connection Strength
1.483
-
Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One. 2012; 7(9):e44543.
Score: 0.333
-
Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011 Nov; 10(11):2052-61.
Score: 0.310
-
Discovery and characterization of inhibitors of human palmitoyl acyltransferases. Mol Cancer Ther. 2006 Jul; 5(7):1647-59.
Score: 0.217
-
Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1. J Pharmacol Exp Ther. 2004 Apr; 309(1):340-7.
Score: 0.183
-
Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15; 63(18):5962-9.
Score: 0.179
-
Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012; 7(7):e41834.
Score: 0.083
-
Targeting NF?B mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther. 2011 Apr 01; 11(7):678-89.
Score: 0.075
-
Palmitoyl acyltransferase assays and inhibitors (Review). Mol Membr Biol. 2009 Jan; 26(1):5-13.
Score: 0.065
-
Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent. Am J Pathol. 2012 Apr; 180(4):1740-50.
Score: 0.020
-
Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. J Hepatol. 2012 Jan; 56(1):137-45.
Score: 0.019